

To Whom It May Concern,

I am Dr. Huang Cheng. Now, I am working in the Department of Thoracic Oncology in Fujian Cancer Hospital.

Upon seeing the WHO EML candidate list posted on this official website, based on my working field and experience, I recommend and support the inclusion of A46. Tislelizumab (non-small cell lung cancer) into WHO EML.

Tislelizumab has a unique structure compared to other PD-1/L1. As an innovative drug, it was supported by National Science and Technology Major Project. In terms of mechanism, Tislelizumab, as the only successfully modified PD-1 monoclonal antibody in the Fc segment, can effectively avoid binding to FcγR on macrophages, thereby eliminating antibody-dependent cell-mediated phagocytosis Effect (ADCP effect), avoiding the effect of the decrease in the number of T cells on anti-tumor efficacy, and at the same time avoids the adverse reactions caused by macrophages. This unique mechanism of tislelizumab may provide reliable efficacy and safety for patients.

Tislelizumab was officially approved for marketing by the National Medical Products Administration (NMPA) of China in 2019. After Tisle was launched, our center immediately introduced and applied it to patients. In clinical use, it has been found that the safety of Tisle is very good, which can effectively prolong the survival period of patients. At the same time, the adverse reactions are relatively mild, and patients benefit significantly.

So far NMPA has approved tislelizumab in nine indications, including first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC) in combination with chemotherapy. In 2020, China included Tisle in the National Reimbursement Drug List, further reducing the drug burden on patients. Especially compared to the Keytruda and Nivolumab drugs in the catalog, the medication burden of patients is relatively light. Therefore, Tisle has economic benefits and can better benefit patient populations in low - and middle-income countries.

Therefore, I urge the 24th Expert Committee on the Selection and Use of Essential Medicines to include tislelizumab in the WHO Model List of Essential Medicines.

Yours Sincerely,
Huang Cheng